Your search for ‘Upadhye Tang’ returned 33 results

Despite the promulgation of the American Invents Act (AIA) in 2012, the concept of prior art has basically stayed the same.

Patents, as one part of intellectual property protection, provide a valuable property right and play an important role in economic development, a reward for innovations...

Artificial Intelligence has revolutionized industries ranging from pharmaceuticals to creative arts, raising profound questions about intellectual property (IP) protection.

Typical patent claims are to products or processes but not both.

The intersection of patent law and regulatory frameworks in the United States presents unique challenges and opportunities for industries involving fertilizers, herbicides, pesticides, rodenticides, and other bulk chemicals.

We previously wrote about product-by-process claims in patent law describing them as an atypical patent claim.

The U.S. pharmaceutical landscape stands at a transformative juncture with several key legislative initiatives currently under Senate consideration.

Intellectual property (IP) is a cornerstone of modern innovation and creativity, providing creators and inventors with the legal means to protect their works, inventions, and brands.

The Supreme Court's unanimous decision in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. fundamentally reshapes the legal landscape for generic drug manufacturers pursuing skinny-label strategies under Section viii carve-outs. By rejecting the Federal Circuit's reader-focused approach and requiring affirmative, purposeful conduct to establish induced infringement, the Court provides substantial new protections while leaving critical questions about implicit inducement and commercial communications pr

The United States Court of Appeals for the Federal Circuit holds unique nationwide jurisdiction over patent cases and specialized federal law, making its composition critically important to innovation and intellectual property enforcement. This analysis examines the Rule of 80 governing senior status eligibility, explains why eligibility dates do not predict actual vacancies, and provides a comprehensive overview of the current court's composition and its implications for patent-dependent industries.